Ratings Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Real-time Estimate Cboe BZX 20:22:45 17/06/2024 BST 5-day change 1st Jan Change
156.7 USD -2.30% Intraday chart for Alnylam Pharmaceuticals, Inc. +2.15% -18.10%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 64% by 2026.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Sales forecast by analysts have been recently revised upwards.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
-16.21% 20.29B
B
+40.80% 53.67B
B-
+34.46% 38.86B
A
-8.05% 38.76B
B
-8.98% 27.27B
C
+10.69% 25.91B
B-
+31.00% 12.78B
B+
+28.51% 12.18B
C+
-1.67% 11.96B
B+
-11.39% 10.79B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ALNY Stock
  4. Ratings Alnylam Pharmaceuticals, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW